Critically, GH treatment had a significant effect on enhancing recovery from these motor deficits at 30 days post-stroke, ameliorating the preferential use of the unaffected limb and reduction in the number of foot fault errors, thus confirming our primary hypothesis. This evidence concerns the gene GH1 and Stroke.